Postdoctoral Researcher
Contact information
Research groups
Andrew Castle
Research Summary
My main research interest is the cellular and molecular mechanisms that underpin neurodegeneration. My previous research focused on prion protein – a key player in the group of dementias known as prion diseases. Here, at the University of Oxford, I study alpha-synuclein, which is associated with Parkinson’s disease and other, rarer neurodegenerative disorders. I am using CRISPR screens to identify proteins that modulate the intracellular trafficking and degradation of alpha-synuclein, which will be validated using a variety of biochemical techniques. The long-term goal of this research is to identify proteins that could be targeted therapeutically to reduce the build-up of toxic alpha-synuclein aggregates in patients.
Recent publications
-
Monitoring α-synuclein ubiquitination dynamics reveals key endosomal effectors mediating its trafficking and degradation
Journal article
Zenko D. et al, (2023), Science Advances, 9
-
Beta-endoproteolysis of the cellular prion protein by dipeptidyl peptidase-4 and fibroblast activation protein
Journal article
Castle AR. et al, (2023), Proceedings of the National Academy of Sciences, 120
-
Investigating CRISPR/Cas9 gene drive for production of disease-preventing prion gene alleles
Journal article
Castle AR. et al, (2022), PLOS ONE, 17, e0269342 - e0269342
-
Susceptibility of Beavers to Chronic Wasting Disease
Journal article
Herbst A. et al, (2022), Biology, 11, 667 - 667
-
Prion protein with a mutant N-terminal octarepeat region undergoes cobalamin-dependent assembly into high–molecular weight complexes
Journal article
Daude N. et al, (2022), Journal of Biological Chemistry, 298, 101770 - 101770
-
Application of high-throughput, capillary-based Western analysis to modulated cleavage of the cellular prion protein
Journal article
Castle AR. et al, (2019), Journal of Biological Chemistry, 294, 2642 - 5291